Eicosanoids and iso-eicosanoids: Constitutive, inducible and transcellular biosynthesis in vascular disease

Thrombosis and Haemostasis

Volumn 79, Issue 4, 1998, Pages 691-705

  Maclouf, Jacques ^a   Folco, Giancarlo ^b   Patrono, Carlo ^c  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DEFIBROTIDE; HYDROXYICOSATETRAENOIC ACID; ICOSANOID; ILOPROST; LEUKOTRIENE; LIPID; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; THROMBOXANE;

ARACHIDONIC ACID METABOLISM; ATHEROSCLEROSIS; BIOSYNTHESIS; HUMAN; ICOSANOID METABOLISM; LIPID OXIDATION; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VASCULAR DISEASE;

EID: 0031978582     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615048     Document Type: Review

References (181)

1. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM et al. The yin and yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. ArteriosclerThromb Vasc Biol 1996; 16: 831-42.
2. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
3. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-92.
4. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991; 68: 11B-15B.
5. Marcus AJ. Multicellular eicosanoid and other metabolic interactions of platelets and other cells. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd edition. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Lippincott Company, Philadelphia, 1994, pp. 590-602.
6. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271: 33157-60.
7. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997; 17: 2309-15.
8. Patrono C. Aspirin as an antiplatelet drug. New Engl J Med 1994; 330: 1287-94.
9. 2 and prostacyclin. Pharmacol Rev 1978; 30: 293-331.
10. 2. J Biol Chem 1994; 269: 13057-60.
11. 2 superfamily of signal transduction enzymes. Trends Biochem Sci 1997; 22: 1-2.
12. Tanabe T, Ullrich V. Prostacyclin and thromboxane synthases. J Lipid Mediators Cell Signalling. 1995; 12: 243-55.
13. Haurand M, Ullrich V, Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450. J Biol Chem 1985; 260: 15059-67.
14. Shen R-F, Tai HH. Immunoaffinity purification and characterization of thromboxane synthase from porcine lung. J Biol Chem 1986; 261: 11592-9.
15. DeWitt D, Smith WL. Purification of prostacyclin synthase from bovine aorta by immunoaffinity chromatography chromatography. Evidence that the enzyme is a hemoprotein. J Biol Chem 1983; 258; 3285-93.
16. Baek SJ, Lee K-D, Shen R-F. Genomic structure and polymorphism of the human thromboxane synthase-encoding gene. Gene 1996; 173: 251-6.
17. Wang L-H, Chen L. Organization of the gene encoding human prostacyclin synthase. Biochem Biophys Res Commun 1996; 226: 631-7.
18. Nakayama T, Soma M, Izumi Y, Kanmatsuse K. Organization of the human prostacyclin synthase gene. Biochem Biophys Res Commun 1996; 221: 803-6.
19. Yokoyama C, Yabuki T, Inoue H, Tone Y, Hara S, Hatae T, Nagata M, Takahashi E-I, Tanabe T. Human gene encoding prostacyclin synthase (PTGIS): genomic organization, chromosomal localization, and promoter activity. Genomics 1996; 36: 296-304.
20. Urade Y, Watanabe K, Hayaishi O. Prostaglandin D, E, and F synthases. J Lipid Mediators Cell Signalling. 1995; 12: 257-73.
21. Funk CD. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid function using lipoxygenase-deficient mice. Biochim Biophys Acta 1996; 1304: 65-84.
22. Yamamoto S. Mammalian lipoxygenases: molecular and catalytic properties. Prostaglandins Leukotrienes Ess Fatty Acids 1989; 35: 219-29.
23. Hamberg M. Stereochemical aspects of fatty acid oxidation: hydroperoxide isomerases. Acta Chem Scand 1996; 50: 219-24.
24. Hamberg M, Samuelsson B. On the specificity of the oxygenation of unsaturated fatty acids catalyzed by soybean lipoxidase. J Biol Chem 1967; 242: 5329-35.
25. Brady HR, Papayianni A, Serhan CN. Potential vascular roles for lipoxins in the "stop programs" of host defense and inflammation. Trends Cardiovasc Med 1995; 5: 186-92.
26. Henderson WR. The role of leukotrienes in inflammation. Ann Int Med 1994; 121: 684-97.
27. Rouzer CA, Matsumoto T, Samuelsson B. Single protein from human leukocytes possesses 5-lipoxygenase and leukotriene A4 synthase activities. Proc Natl Acad Sci USA 1986; 83: 857-61.
28. Murphy RC, Hammarström S, Samuelsson B. Leukotriene C: a slow reacting substance (SRS) from murine mastocytoma cells. Proc Natl Acad Sci USA. 1979; 76: 4275-9.
29. Fitzpatrick F, Murphy RC. Cytochrome P-450 metabolism of arachidonic acid: formation and biological actions of "epoxygenase"-derived eicosanoids. Pharmacol Rev 1989; 40: 229-41.
30. Schwartzman M, McGiff JC. Renal cytochrome P450 metabolism of arachidonic acid; biochemistry and molecular biology. In S Yamamoto and WL Smith (eds) Molecular Biology of the Arachidonic acid Cascade. Elsevier, Amsterdam 1995; pp. 229-42.
31. Harder DR, Navayanan J, Gebremedhin D, Roman RJ. Transduction of physical force by the vascular wall. Role of phospholipase C and cytochrome P450 metabolites of arachidonic acid. Trends Cardiovasc Med 199; 5: 7-14.
32. 1. Eur J Pharmacol 1971; 14: 66-70.
33. Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair I, FitzGerald GA. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 1986; 72: 590-4.
34. 2 in man: identification of twenty urinary metabolites. J. Biol. Chem. 1981; 256: 8384-93.
35. 2 in the human circulation. Anal Biochem 1986; 155: 198-205.
36. 2 in man. Biochim Biophys Acta 1989; 992: 66-70.
37. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA. 1975; 72: 2994-8.
38. 2. Nature 1985; 315: 511-3.
39. 2 in the cynomolgus monkey. Biochim Biophys Acta 1989; 992: 71-7.
40. Patrono C, Davi G, Ciabattoni G. Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. Trends Cardiovasc Med 1992; 2: 15-20.
41. 4 elimination and metabolism in normal human subjects. J Biol Chem 1990; 265: 21771-8.
42. 4 into vascular compartment in healthy subjects. Am J Physiol 1992; 263: H244-H9.
43. van der Ouderaa FJ, Buytenhec M, Nugteren DH, van Dorp DA. Purification and characterisation of prostaglandin endoperoxide synthetase from sheep vesicular glands. Biochim Biophys Acta 1977; 487; 315-31.
44. Funk CD, Funk LB, Kennedy ME, Pong AS, FitzGerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression and gene chromosomal assignment. FASEB J 1991; 5: 2304-12.
45. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS 10, a phorbol ester tumor promotor inducible mRNA from Swiss 3T3 cells encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266: 12866-72.
46. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin G synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-6.
47. Jones DA, Carlton DP, Mc Intyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 9049-54.
48. Smith WL, De Witt DL. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 1996; 62: 167-215.
49. Habib A, Créminon C, Frobert Y, Grassi J, Pradelles P, Maclouf J. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the C-terminal region of the cyclooxygenase-2. J Biol Chem 1993; 268: 23448-54.
50. Laneuville O, Breuer DK, Xu N, Huang ZH, Gage DA, Watson JT, Lagarde M, De Witt DL, Smith WL. Fatty acid substrate specificities of human prostaglandin endoperoxide H synthases-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)-Octadecatrienoic acids from δ-linolenic acid. J Biol Chem 1995; 270: 19330-6.
51. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nature Structural Biol 1996; 3: 927-33.
52. Kurumbail, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384: 644-8.
53. Otto JC, De Witt DL and Smith WL. N-glycosylation of prostaglandin endoperoxide synthases-1 and -2 and their orientation in the endoplasmic reticulum. J Biol Chem 1993; 268: 18234-42.
54. Picot D, Garavito RM. Prostaglandin H synthase: implications for membrane structure. FEBS Lett 1994; 346: 21-5.
55. 2 synthase-1. Nature 1994; 367: 243-9.
56. Morita I, Schindler M, Rigier MK, Otto JC, Hori T, De Witt DL, Smith WL. Different intracellular locations for prostaglandin endoperoxide H synthases-1 and -2. J Biol Chem 1995; 270: 10902-8.
57. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 125-40.
58. Asano K, Lilly CM, Drazen JM. Prostaglandin G/H synthase-2 is the constitutive and dominant isoform in cultured human lung epithelial cells Am J Physiol 1996; 271: L126-31.
59. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232-5.
60. Smith WL, Lands WE. Stimulation and blockade of prostaglandin biosynthesis. J Biol Chem 1971; 246: 6700-2.
61. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate protein fraction. J Clin Invest 1975; 56: 624-32.
62. Lecomte M, Laneuville O, Ji C, De Witt DL, Smith WL. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 1994; 269: 13207-15.
63. Claria J, Serhan C. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cells-leukocyte interactions. Proc Natl Acad Sci USA 1995; 92: 9475-9.
64. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-72.
65. 2 synthase. Nature Structural Biol 1995; 2: 637-43.
66. Quellet M, Percival MD. Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J 1995; 306: 247-51.
67. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Créminon C, Maclouf J, Patrono C. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmac Exp Ther 1994; 271: 1705-12.
68. Panara MR, Greco A, Santini G, Sciulli MG, Rotonda MT, Padovano R, di Giamberardino M et al. Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothio-phenyl)-1-indanone (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. Br J Pharmac 1995; 116: 2429-34.
69. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 1990; 87: 9383-7.
70. Lynch SM, Morrow JD, Roberts LJ II, Frei B. Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. J Clin Invest 1994; 93: 998-1004.
71. 2α by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem 1996; 271: 8919-24.
72. Beaudeux JL, Césarini ML, Gardès-Albert M, Maclouf J, Esposito B, Peynet J, Tedgui A. Native and gamma radiolysis-oxidized lipoprotein(a) increase the adhesiveness of rabbit aoric endothelial cells. Atheroscleros 1997; 132: 29-35.
73. 2α: an index of oxidative stress in vivo. J Clin Invest 1997; 100: 2028-34.
74. 2α. J Biol Chem 1995; 270: 9800-7.
75. 2-isoprostane formation. Br J Pharmacol 1996; 118: 1285-93.
76. 2α excretion in man. J Pharm Exp Therapeut 1995; 275: 94-100.
77. 2α is not mediated by thromboxane receptor isoforms J Biol Chem 1996; 271: 14916-24.
78. 2α increases platelet adhesion and the expression of adhesion molecule. Thromb Haemost 1997 (Suppl): PS2728 (Abstract).
79. 2-isoprostanes) in smokers. N Engl J Med 1995; 332: 1198-203.
80. 2α levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Letters 1995; 368: 225-9.
81. 2α is increased in hypercholesterolemia. Arterioscler Tromb Vase Biol 1997; 17: 3230-5.
82. Marcus AJ. Thrombosis and inflammation as multicellular processes: pathophysiologic significance of transcellular metabolism. Blood 1990; 76: 1903-7.
83. Ross R. The pathogenesis of atherosclerosis, a perspective for the 1990s. Nature 1993; 362: 801-9.
84. Marcus AJ and Hajjar DP. Vascular transcellular signaling. J Lipid Res 1993; 34: 2017-31.
85. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
86. Sporn MB, Roberts AB: Autocrine secretion-10 years later. Ann Int Med 1992; 117: 408-14.
87. Bunting S, Gryglewski R, Moncada S, Vane JR. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 1976; 12: 897-913.
88. Marcus AJ, Weksler BB, Jaffe EA, Broekman MJ. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 1980; 66: 979-86.
89. 4. J Biol Chem 1984; 259: 11403-7.
90. 4 via transcellular biosynthesis. Proc Natl Acad Sci USA 1986; 83: 1349-53.
91. 4 synthesized by polymorphonuclear leukocytes. J Biol Chem 1986; 261: 16466-72.
92. 4. Eur J Biochem 1988; 173: 93-100.
93. Maclouf J, Murphy RC, Henson PM. Transcellular sulfidopeptide leukotriene biosynthetic capacity of vascular cells. Blood 1989; 74: 703-7.
94. Maclouf J, Henson P, Murphy RC. Transcellular biosynthesis of sulfidopeptide leukotrienes during receptor-mediated stimulation of human neutrophil/platelet mixtures. Blood 1990; 76: 1838-44.
95. 4 synthesis: requirement for transcellular leukotriene A4 metabolism. Biochim Biophys Acta 1987; 922: 125-35.
96. 4 by human platelets. J Biol Chem 1988; 263: 174-81.
97. 4 to cysteinyl-containing leukotrienes by human platelets. Eur J Biochem 1988; 178: 81-6.
98. 4 by human platelets and endothelial cells. Archives Biochem Biophys 1992; 298: 544-52.
99. 4 in different human tissues is attributable to distinct membrane bound biosynthetic enzymes. J Biol Chem 1997; 272: 10182-7.
100. Brady HR, Serhan CN. Adhesion promotes transcellular leukotriene biosynthesis diring neutrophil-glomerular endothelial cell interactions: inhibition by antibodies against CD18 and L-selectin. Biochem Biophys Res Commun 1992; 186: 1307-14.
101. Edenius C, Haeggström J, Lindgren JA. Transcellular conversion of endogenous arachidonic acid to lipoxins in mixed human platelet-granulocyte suspensions. Biochem Biophys Res Commun 1988; 157: 801-7. Erratum Biochem Biophys Res Commun 1989; 159: 370.
102. Romano M, Chen XS, Takahashi Y, Yamamoto S, Funk CD, Serhan CN. Lipoxin synthase activity of human platelet 12-lipoxygenase. Biochem J 1993; 296: 127-33.
103. Lucchesi BR, Mullane KM. Leukocytes and ischemia-induced myocardial injury. Annu Rev Pharmacol Toxicol 1986; 26: 201-24.
104. Friedman GD, Klatsky AL, Siegelaub AB. The leukocyte count as a predictor of myocardial infarction. N Engl J Med 1974; 290: 1275-8.
105. Noble B, Ken K, Taverne J, Dipirro J, VanLiew J, Dijkstra C, Janossy G, Poulter LW. Mononuclear cells in glomeruli and cytokines in urine reflect the severity of experimental proliferative immune-complex glomerulonephritis, Clin Exp Immunol 1990; 80: 281-7.
106. Brigham KL, Meyrick B. Interactions of granulocytes with the lungs. Circ Res 1984; 54: 62-70.
107. Hickman P, McCollum PT, Belch JF. Neutrophils may contribute to the morbidity and mortality of claudicants. Br J Surgery 1994; 81: 790-8.
108. Harlan JM. Leukocyte-endothelial interactions. Blood 1985; 65: 513-25.
109. Grimminger F, Kreusler B, Schneider U, Becker G, Seeger W. Influence of microvascular adherence on neutrophil leukotriene generation. Evidence for cooperative eicosanoid synthesis. J Immunol 1990; 144: 1866-72.
110. 4 in blood free perfused lungs. J Immunol 1988; 141: 2431-6.
111. Palmentier R, Krump E, Rocheleau H, Laviolette M, Borgeat P. Dynamics of 5-LO product synthesis by human neutrophils and eosinophils in plasma and salt solution. Inflammation Res 1995; 44: S259.
112. 4 by human eosinophils. J Biol Chem 1989; 264: 12885-9.
113. NF Voelkel, J Czartolomna, J Simpson, RC Murphy, FMLP causes eicosanoi-dependent vasoconstriction and edema in lungs from endotoxin-primed rats. Am Rev Respir Dis 1992; 145: 701-11.
114. Grimminger F, Kreusler B, Schneider U, Witzeleben EV, Walmrath D, Neppert J, Seeger W. Human leukoagglutininating antibody evokes cooperative leukotriene synthesis in pulmonary microvasculature; model of transfusion-related acute lung injury. Circ Res 1991; 68: 503-12.
115. Maugeri N, Evangelista V, Piccardoni P, Dell'Elba G, Celardo A, deGaetano G, Cerletti C. Transcellular metabolism of arachidonic acid: increased platelet thromboxane generation in the presence of activated polymorphonuclear leukocytes. Blood 1992; 80: 447-51.
116. 4 from human polymorphonuclear leukocytes. J Biol Chem 1996; 271: 17944-8.
117. 4 and 12-HETE from alveolar epithelial cell-derived arachidonic acid. Am Rev Respir Dis 1988; 138: 928-35.
118. Chavis C, Vachier I, Chanez P, Bousquet J, Godard P. 5(S),15(S)-dihydroxyeicosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors.J Exp Med 1996; 183: 1633-43.
119. Forman MB, Virmani R, Puett DW. Mechanisms and therapy of myocardial reperfusion injury. Circulation 1990; 81: 69-78.
120. Fisher TC, Meiselmann HJ. PMN in ischemic vascular disease. Thromb Res 1994; 74: 21-34.
121. Sala A, Rossoni R, Buccellati C, Berti F, Folco G, Maclouf J: Formation of sulphidopeptide-leukotrienes by cell-cell interaction causes coronary vasoconstriction in isolated, cell-perfused heart of rabbit. Br J Pharmac 1993; 110: 1206-12.
122. Rossoni G, Sala A, Berti F, Testa T, Buccellati C, Molta C, Muller-Peddinghaus R, Maclouf J, Folco G: Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J Pharm Exp Ther 1996; 276: 335-41.
123. Evers AS, Murphree S, Saffitz JE, Jakschik BA, Needleman P. Effect of endogenously produced leukotrienes, thromboxane and prostaglandins on coronary vascular resistance in rabbit myocardial infarction. J Clin Invest 1985; 75: 992-9.
124. Sala A, Aliev GM, Rossoni G, Berti F, Buccellati C, Burnstock G, Folco G, Maclouf J: Morphological and functional changes of coronary vasculature caused by transcellular biosynthesis of sulfidopeptide leukotrienes in isolated heart of rabbit. Blood 1996; 87: 1824-32.
125. Semb AG, Ytrehus K, Vaage J, Myklebust R. Cardiac injury by activated PMN: effect of cyclooxygenase and lipoxygenase inhibition evaluated by electron microscopy morphometry. J Mol Cell Cardiol 1996; 28: 311-20.
126. Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Naganishi S, Narumiya S. Cloning and expression of cDNA for a human thromboxane A, receptor. Nature 1991; 349: 617-20.
127. 2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994; 94: 1662-7.
128. 2 receptor. J Biol Chem 1994; 269: 19256-61.
129. 60 to leu mutation. J Clin Invest 1996; 97: 949-56.
130. 2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. Proc Natl Acad Sci USA 1990; 265: 683644.
131. Habib A, Vezza R, Créminon C, Maclouf J, FitzGerald G, Rapid, agonist-dependent phosphorylation in vivo of human thromboxane receptor isoforms. Minimal involvement of protein kinase C. J Biol Chem 1997; 272: 7191-200.
132. Boie Y, Rushmore TH, Darmon-Goodwin A, Grygorczyk R, Slipetz DM, Metters KM, Abramovitz M Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem 1994; 269: 12173-8.
133. Oida H, Namba T, Sugimoto Y, Ushikubi F, Ohishi H, Ichikawa A, Narumiya In situ hybridization studies of prostacyclin receptor mRNA expression in various organs. Br J Pharmacol 1995; 116: 2828-37.
134. Smyth EM, Nestor PV, FitzGerald GA Agonist-dependent phsophorylation of an epitope-tagged human prostacyclin receptor. J Biol Chem 1996; 271: 33698-704.
135. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A, Oh-Ishi S, Narumiya S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997; 388: 678-82.
136. Murata T, Matsuoka T, Yoshida N, Hirata M, Ushikubi F, Narumiya S. Analysis of IP receptor-deficient mice. Keystone symposia. Lipid mediators: recent advances in molecular biology, understanding of regulation and pharmacology 1997 (Abstract).
137. Ushikubi F, Hirata M, Narumiya S. Molecular biology of prostanoid receptors; an overview. J Lipid Mediators Cell Signalling 1995; 12: 343-59.
138. Bernard C, Tedgui A: Cytokine network and the vessel wall. Insights into the septic shock pathogenesis. Eur Cytokine Netw 1992; 3: 19-33.
139. Di Rosa M, Ialenti A, Sautebin L. Interaction between nitric oxide and cyclooxygenase pathways. Prostaglandins Leukotrienes Ess Fatty Acids 1995; 54: 229-38.
140. Salvemini D, Seibert K, Masferrer JL, Misko TP, Currie MG, Needleman P. Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest 1994; 93: 1940-7.
141. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993; 90: 7240-4.
142. Davidge ST, Baker PN, McLaughlin MK, Roberts JM. Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase. Circ Res 1995; 77: 274-83.
143. Tsai A, Wei C, Kulmacz RJ. Interaction between nitric oxide and prostaglandin H synthase. Arch Biochem Biophys 1994; 313: 367-72.
144. Habib A, Bernard Lebret M. Créminon C, Esposito B, Tedgui A, Maclouf J Regulation of the expression of cyclooxygenase-2 by nitric oxide in rat peritoneal macrophages. J Immunol 1997; 158: 3845-51.
145. Sautebin L, Ialenti A, Ianaro A, Di Rosa M. Modulation by nitric oxide of prostaglandin biosynthesis in the rat. Br J Pharmacol 1995; 114: 323-8.
146. Stadler J, Harbrecht BG. Di Silvio M, Curran RD, Jordan ML, Simmons RL, Billiar TR. Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat Kupffer cells. J Leukoc Biol 1993; 53: 465-72.
147. Henrion D, Dechaux E., Dowell FJ, Maclouf J, Samuel J-L, Levy BI, Michel J-B. Alteration of flow-induced dilation in mesenteric resistance arteries of L-NAME treated rats is partially associated to induction of cyclooxygenase-2. Brit J Pharmacol 1997; 121: 83-90.
148. 2 of cytokine-elicited nitric oxide synthesis in rat liver macrophages. Biol Chem Hoppe-Seyler 1992; 373: 897-902.
149. Pang L, Hoult JRS. Induction of cyclooxygenase and nitric oxide synthase in endotoxin-activated J774 macrophages is differentially regulated by indomethacin: enhanced cyclooxygenase-2 protein expression but reduction of inducible nitric oxide synthase. Eur J Pharmacol 1996; 317: 151-5.
150. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-6.
151. Thun MJ. Aspirin, NSAIDs, and digestive tract cancers. Cancer Metastas Rev 1994; 13: 269-77.
152. Levy G. Prostaglandin H synthases, non-steroidal anti-inflammatory drugs, and colon cancer. FASEB J 1997; 11: 234-47.
153. Rimarachin JA, Jacobson JA, Szabo P, Maclouf J, Créminon C, Weksler B B. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscleros Thrombos 1994; 14: 1021-31.
154. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 1995; 83: 495-501.
155. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Malher JF, Lee CA, Goulding EH, Kluckman KD, Kim HS, Smithies O. Prostaglandin synthase-1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83: 483-92.
156. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Malher JF, Kluckman KD, Ledford A, Lee CA. Smithies O. Prostaglandin synthase-2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83: 473-82.
157. Prescott SM, White RL. Self-promotion? Intimate connection between APC and prostaglandin H synthase-2. Cell 1996; 87: 783-6.
158. Δ716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 1996; 87: 803-9.
159. Ballif BA, Mincek NV, Barratt JT, Wilson ML, Simmons DL. Interaction of cyclooxygenases with an apoptosis-and autoimmunity-associated protein. Proc Natl Acad Sci USA 1996; 93: 5544-9.
160. Karim S, Habib A. Lévy-Toledano S, Maclouf J. Cyclooxygenases-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 1996; 271: 12042-8.
161. Barry OP, Pratico D, Lawson JA, FitzGerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997; 99: 2118-27.
162. FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065-8.
163. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-9.
164. Vejar M, Fragasso G, Hackett D, Lipkin DP, Maseri A, Born GVR, Ciabattoni G, Patrono C. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemost 1990; 63: 163-8.
165. Cipollone F, Patrignani P, Greco A, Panara MR,.Padovano R, Cuccurullo F, Patrono C et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997; 96: 1109-16.
166. 2 reduces the number of "slow moving" leukocytes in hamster cheek pouch venules. J Physiol 1978; 280: 55-6.
167. Erlansson M, Bergqvist D, Person NH, Svensjo E. Modification of postischemic increase of PMN adhesion and vascular permeability in the hamster by Iloprost. Prostaglandins 1991; 41: 157-68.
168. Simpson PJ, Mickelson J, Fantone JC, Gallagher KP, Lucchesi BR. Iloprost inhibits PMN function in vitro and in vivo and limits experimental infarct size in canine heart. Circ Res 1987; 60: 666-73.
169. Rossoni G, Sala A, Buccellati C, Maclouf J, Folco G, Berti F. Prostacyclin prevents polymorphonuclear leukocyte-dependent coronary ischemia due to transcellular biosynthesis of sulphido-peptide leukotrienes in perfused heart of rabbit. J Cardiovasc Pharmacol 1996; 27: 680-5.
170. Buccellati C, Rossoni G, Bonazzi A, Berti F, Maclouf J, Folco G, Sala A. Nitric oxide modulation of transcellular biosynthesis of Cys-leukotrienes in rabbit leukocyte-perfused heart. Br J Pharmacol 1997; 120: 1128-34.
171. Zoldhelyi P, McNatt J, Xu X-M, Loose-Mitchell D, Meidell RS, Clubb Jr FJ, Buja M, Willerson JT, Wu KK. Prevention of arterial thrombosis by
172. Shoonjans K, Staels B, Auwerx J. The peroxisome activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996; 1302: 93-109.
173. 2 is a ligand for the adipocyte determination factor PPARγ Cell 1995; 83: 803-12.
174. Smith WL, DeWitt D. Do they still have headaches? Cell 1995; 83: 345-8.
175. 2α. Biochim Biophys Acta 1991; 1091: 364-9.
176. Hertz R, Berman I, Keppler D, Bar-Tana J. Activation of gene transcription by prostacyclin analogues is mediated by the peroxisome-proliferators-activated receptor (PPAR). Eur J Biochem 1996; 235; 242-7.
177. Aubert J, Ailhaud G, Négrel R. Evidence for a novel regulatory pathway activated by (carba)prostacyclin in preadipose and adipose cells. FEBS Letters 1996; 397: 117-21.
178. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA. Differential activation of peroxisome proliferatoractivated receptors by eicosanoids. J Biol Chem 1996; 270: 23975-83.
179. 4 pathway to inflammation control. Nature 1996; 384: 39-43.
180. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors δ and γ. Proc Natl Acad Sci USA 1997; 94: 4312-7.
181. Ledwith BJ, Pauley CJ, Wagner LK, Rokos CL, Alberts DW, Manam S. Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecaoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells. J Biol Chem 1997; 272: 3707-14.